Viatris (VTRS) Stock Forecast & Price Target

Viatris is attractive because its core generics franchise appears to be stabilizing after several years of divestitures and disruptions, with developed-market generics returning to growth in 1H26 and a sizable patent-cliff opportunity ahead as $175B of branded drug revenue comes off patent between 2025-2030. Growth is further supported by a shift toward more durable complex generics and branded launches, while management’s target to capture roughly 70% of the patent-cliff pool and expand complex-generic launches by 35% reinforces the earnings recovery story. On top of that, the pipeline adds meaningful upside through fast-acting meloxicam, contraceptive patches, selatogrel, and cenerimod, giving Viatris multiple near- and longer-term catalysts that could support revenue, EBITDA, and valuation re-rating.

Viatris is burdened by a base business that may generate only modest growth, while its fortunes remain heavily tied to higher-risk pipeline outcomes such as cenerimod and selatogrel, both of which face meaningful clinical and timing uncertainty. The company’s core exposure to generics and biosimilars, roughly 40% of sales, leaves it vulnerable to pricing and competitive pressure, especially as U.S. generics could become a drag if complex-generic mix improvement is not enough to offset erosion. At the same time, dependence on legacy products representing about 60% of sales, plus regional risks in Greater China and JANZ, limits confidence that earnings can sustainably re-rate without a stronger biosimilars vertical.